Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0318849 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Stefano Guzzinati und 10 weiteren Autor:innen. Beteiligte Einrichtung: Veneto Cancer Registry, Epidemiological Department, Azienda Zero, Padova, Italy. Hauptthemen laut MEDLINE: Terminal Care, Neoplasms, Health Care Costs. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Themen: Onkologische Pflege, Palliativpflege
Abstract (Originalsprache)
Objectives
The study aims to analyze care and cost patterns in the Veneto region for cancer patients in the final phase of their disease.
Methods
The study cohort includes adult patients alive on 1.1.2018, which have been diagnosed with cancer at the age 15+ in a 28-years period, spanning from 1990 to 2017, and died within 12 months from prevalence date. The end-of-life (EOL) prevalent cases included in the study cohort are identified by the Veneto Tumor Registry. Primary tumors considered in the analysis are colon, rectum, skin melanoma, female breast, thyroid. Patient monthly average EOL costs, patient annual average EOL costs and total regional costs have been estimated separately for each cancer site/sex/age group/health care service database.
Results
The estimated EOL total cost, for the five analyzed cancer types in the Veneto Region, is approximately 53 million euros. Costs associated with cancer treatment tend to increase in the final phase of the disease. In general, Hospital Admission is the main driver cost in all types of cancer considered, with the only exception in melanoma, where Hospital Drugs features the highest contribution. Moreover, costs differ significantly depending on the type of cancer, gender, and age, revealing highest average costs associated with younger patients.
Conclusions
This study provides a comprehensive analysis of healthcare budget distribution in the last year of life, enabling healthcare planners to predict cancer burden in the future. This model can be applied to other Italian regions and countries with different healthcare systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Veneto Cancer Registry, Epidemiological Department, Azienda Zero, Padova, Italy.
- National Centre for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy.
- Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
- Department of Cardiological, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy.
ORCID-Profile: Stefano Guzzinati, Alessandra Andreotti, Silvia Gori
Förderung
- Ministero della Salute
Zitieren
APA
Guzzinati, S., Andreotti, A., Lopez, T., Gori, S., Gagliani, A., Mallone, S., Pierannunzio, D., Tavilla, A., Buja, A., Zorzi, M., & Francisci, S. (2025). Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study. PLOS ONE. https://doi.org/10.1371/journal.pone.0318849
Vancouver
Guzzinati S, Andreotti A, Lopez T, Gori S, Gagliani A, Mallone S, et al. Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study. PLOS ONE. 2025. doi:10.1371/journal.pone.0318849
BibTeX
@article{Guzzinati2025,
author = {Guzzinati, Stefano and Andreotti, Alessandra and Lopez, Tania and Gori, Silvia and Gagliani, Alberto and Mallone, Sandra and Pierannunzio, Daniela and Tavilla, Andrea and Buja, Alessandra and Zorzi, Manuel and Francisci, Silvia},
title = {Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0318849}
}
EUVIMED